acetylcysteine and Cryptogenic Fibrosing Alveolitis

acetylcysteine has been researched along with Cryptogenic Fibrosing Alveolitis in 69 studies

Research

Studies (69)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (4.35)29.6817
2010's58 (84.06)24.3611
2020's8 (11.59)2.80

Authors

AuthorsStudies
Banfield, L; Coyne, J; Cui, S; Guy, B; Helmeczi, W; Husnudinov, R; Jones, A; Khalid, MF; Kolb, MR; Mah, J; Pitre, T; Scallan, C; Su, J; Zeraatkar, D; Zhang, M1
Cao, F; Jiao, Y; Li, G; Liu, H; Pang, Q; Wei, W1
Cooper, CB; Flaherty, KR; Kim, JS; Lasky, JA; Martinez, FJ; Murray, S; Noth, I; Oldham, JM; Podolanczuk, AJ; Raghu, G; Spino, C1
Singh, S; Wairkar, S1
Cao, Y; Zhang, XL; Zheng, B1
Bonella, F; Kreuter, M; Li, X; Oltmanns, U; Peng, S; Shi, H; Wei, L; Yin, D1
Bando, M; Hattori, N; Homma, S; Inase, N; Johkoh, T; Kataoka, K; Kato, M; Kishaba, T; Kishi, K; Kondoh, Y; Kuwano, K; Mukae, H; Nishioka, Y; Okamoto, M; Saito, T; Sakai, F; Sakamoto, S; Sasaki, S; Suda, T; Taguchi, Y; Takizawa, H; Tanino, Y; Yatera, K1
Noth, I; Podolanczuk, AJ; Raghu, G1
Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H1
Adegunsoye, A; Chen, LW; Chung, JH; Hsu, S; Husain, A; Lee, C; Montner, S; Noth, I; Oldham, JM; Strek, ME; Vij, R; Witt, LJ1
Azuma, A; Bando, M; Date, H; Ebina, M; Fukuoka, J; Gemma, A; Goto, Y; Hasegawa, Y; Hattori, N; Homma, S; Inase, N; Inoue, Y; Ishii, Y; Izumi, S; Johkoh, T; Kido, T; Kishaba, T; Kishi, K; Miyamoto, A; Mukae, H; Nakayama, T; Nishioka, Y; Ogura, T; Sakamoto, S; Sasaki, S; Suda, T; Sugino, K; Taguchi, Y; Takahashi, H; Takahashi, K; Taniguchi, H; Watanabe, K; Yokoyama, A; Yoshino, I1
Blokland, KEC; Burgess, JK; Grainge, C; Hogaboam, CM; Jaffar, J; Khalil, N; Knight, DA; Mutsaers, SE; Pechkovsky, DV; Prêle, CM; Read, J; Reid, AT; Schuliga, M; Waters, DW; Westall, G1
Guo, J; Li, B; Li, W; Pan, Y; Wang, F; Wang, Z; Wu, Y1
Chen, MJ; Ding, YX; Tong, ZQ; Yang, GL1
Beuschel, RT; Bui, SN; Cannon, B; Chhina, MK; Ellis, E; Grant, GM; Lemma, M; Liberti, EM; Nathan, SD; Rodriguez, LR1
Liu, JP; Lv, XD; Pang, LJ1
Gasbarrini, A; Gibiino, G; Richeldi, L; Varone, F1
Hashemi Sadraei, N; Masjedi, MR; Riahi, T1
Alfaro, TM; Cordeiro, CR; Freitas, S1
Ancochea, J; Bollo, E; Fernández-Fabrellas, E; Franquet, T; Molina-Molina, M; Montero, MA; Serrano-Mollar, A; Xaubet, A1
Bodlet, A; Dahlqvist, C; Jamart, J; Maury, G1
Ancochea, J; Valenzuela, C1
Kondoh, Y; Taniguchi, H1
Homma, S; Ishida, F; Isobe, K; Itoh, T; Muramatsu, Y; Sakamoto, S; Satoh, K; Sugino, K1
Aguilaniu, B; Bouquillon, B; Cadranel, J; Carré, P; Cordier, JF; Cottin, V; Crestani, B; Dalphin, JC; Danel, C; Delaval, P; Faivre, JB; Ferreti, G; Israel-Biet, D; Just, N; Kessler, R; Kouzan, S; Lebargy, F; Marchand Adam, S; Philippe, B; Prévot, G; Reynaud-Gaubert, M; Stach, B; Thivolet-Béjui, F; Valeyre, D; Wallaert, B1
Zhang, DP1
Anstrom, KJ; de Andrade, JA; King, TE; Martinez, FJ; Raghu, G1
Collard, HR; Ryerson, CJ1
Ehlers-Tenenbaum, S; Herth, FJ; Heussel, CP; Kahn, N; Kreuter, M; Oltmanns, U; Palmowski, K; Puderbach, M; Schnabel, PA; Träger, A; Warth, A; Wenz, H; Wiebel, M1
Kang, S1
Covvey, JR; Mancl, EE1
Cottin, V1
Homma, S; Sakamoto, S; Sugino, K1
Homma, S; Ishida, F; Isobe, K; Kikuchi, N; Muramatsu, Y; Sakamoto, S; Sano, G; Satoh, K; Sugino, K; Takai, Y1
Nambiar, AM; Velez, MI1
Einecke, D1
Andreas, S; Bahmer, T; Behr, J; Claussen, M; Gläser, S; Grohé, C; Held, M; Herth, FJ; Hoeper, MM; Höffken, G; Huber, RM; Kirschner, J; Klotsche, J; Koch, A; Kohlhäufl, M; Koschel, D; Kreuter, M; Meyer, FJ; Neurohr, C; Pittrow, D; Randerath, W; Schwaiblmair, M; Skowasch, D; Welte, T; Wilkens, H; Wirtz, H1
Clegg, AJ; Colquitt, JL; Copley, VR; Loveman, E; O'Reilly, KM; Scott, DA1
Anstrom, KJ; Huang, Y; Lee, C; Ma, SF; Martinez, FJ; Noth, I; Oldham, JM; Raghu, G; Schwartz, DA; Strek, ME; Valenzi, E; Vij, R; Witt, L1
Lozano-Wilhelmi, M1
Blackwell, TS; Kropski, JA; Lawson, WE1
Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G1
Beyene, J; Brozek, J; Garcia, CC; Neupane, B; Raghu, G; Richeldi, L; Rochwerg, B; Schünemann, H; Zhang, Y1
Amano, M; Honda, K; Kawabe, R; Matsubayashi, M; Matsushima, H; Nishizawa, T; Oba, T; Okuda, R1
Homma, S; Ishida, F; Morita, T; Muramatsu, Y; Sugino, K; Tatebe, J1
Collard, HR; Wijsenbeek, MS1
Albera, C; Beck, J; Behr, J; Bendstrup, E; Crestani, B; Günther, A; Koschel, D; Kreuter, M; Lin, CY; Olschewski, H; Sköld, CM; Wallaert, B; Wells, A; Wuyts, W1
Liu, J; Sun, T; Zhao, W1
Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Rogliani, P1
Biju, G; Jyothi, E; Kumar, NK; Narayan, KV; Suraj, KP1
Che, C; Chi, F; Dong, F; Liu, L; Song, Q; Wang, Y; Zhang, C; Zhang, L1
Guo, F; Song, X; Yu, W1
Martinez, F; Noth, I; Raghu, G1
Albera, C; Behr, J; Crestani, B; Kirchgaessler, K; Wells, A1
Chang, S; Diamantopoulos, A; Esser, D; LeReun, C; Maher, TM; Rinciog, C; Watkins, M1
Wolters, PJ1
Behr, J; Boissard, G; Buhl, R; Costabel, U; De Vuyst, P; Dekhuijzen, RP; Demedts, M; Flower, CD; Jansen, HM; Lankhorst, I; Laurent, F; MacNee, W; Nicholson, AG; Petruzzelli, S; Rodriguez-Becerra, E; Sardina, M; Thomeer, M; van den Bosch, JM; Verbeken, EK; Verschakelen, J; Wallaert, B1
Eckman, MH; Hagaman, JT; Kinder, BW1
Costabel, U; Cu, A; Guzman, J; Nakamura, S; Sarria, R; Ye, Q1
Bando, M; Hosono, T; Mato, N; Nakaya, T; Ohno, S; Sugiyama, Y; Yamasawa, H1
Agnese, S; Avvedimento, EV; Bocchino, M; Fagone, E; Gabrielli, A; Grieco, D; Sanduzzi, A; Svegliati, S; Vancheri, C1
Behr, J; Costabel, U; Worth, H1
McGrath, EE; Millar, AB1
Azuma, A; Homma, S; Kudoh, S; Mochiduki, Y; Nakata, K; Ogura, T; Sugiyama, Y; Takeuchi, M; Taniguchi, H; Yoshimura, K1
Elton, TS; Gupta, NN; Gurney, TO; Haley, BE; Kotha, SR; Magalang, UJ; Malireddy, S; Marsh, CB; Parinandi, NL; Patel, RB; Sauers, LA1
Behr, J1
Behr, J; Costabel, U; Cottin, V; Poletti, V; Wells, AU1
Chen, L; Li, J; Li, S; Li, W; Su, X; Yan, G; Yang, X1
Adamali, HI; Maher, TM1

Reviews

18 review(s) available for acetylcysteine and Cryptogenic Fibrosing Alveolitis

ArticleYear
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.
    Thorax, 2022, Volume: 77, Issue:12

    Topics: Acetylcysteine; Adult; Azathioprine; Humans; Idiopathic Pulmonary Fibrosis; Network Meta-Analysis; Sildenafil Citrate

2022
Clinical efficacy of Chinese herbs for supplementing qi and activating blood circulation combined with N-acetylcysteine in the treatment of idiopathic pulmonary fibrosis: A systematic review and network meta-analysis.
    PloS one, 2022, Volume: 17, Issue:3

    Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Network Meta-Analysis; Oxygen; Qi; Treatment Outcome

2022
Efficacy of N-acetylcysteine plus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    BMC pulmonary medicine, 2023, Nov-29, Volume: 23, Issue:1

    Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Treatment Outcome

2023
Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis.
    BMC pulmonary medicine, 2020, May-07, Volume: 20, Issue:1

    Topics: Acetylcysteine; Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity

2020
Japanese guideline for the treatment of idiopathic pulmonary fibrosis.
    Respiratory investigation, 2018, Volume: 56, Issue:4

    Topics: Acetylcysteine; Administration, Inhalation; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Disease Progression; Drug Therapy, Combination; Evidence-Based Medicine; Glycine; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Japan; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic; Prognosis; Pyridones; Quality of Health Care; Sulfonamides; Survival Rate

2018
Chinese herbal medicines compared with N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: Protocol for a systematic review.
    Medicine, 2018, Volume: 97, Issue:44

    Topics: Acetylcysteine; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Idiopathic Pulmonary Fibrosis; Quality of Life; Randomized Controlled Trials as Topic; Systematic Reviews as Topic; Total Lung Capacity; Treatment Outcome

2018
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy.
    European review for medical and pharmacological sciences, 2019, Volume: 23, Issue:14

    Topics: Acetylcysteine; Anti-Bacterial Agents; Antioxidants; Colistin; Disease Progression; Drug Synergism; Drug Therapy, Combination; Humans; Idiopathic Pulmonary Fibrosis; Lung; Microbiota

2019
[How to face the current status of therapies for idiopathic pulmonary fibrosis].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2013, Volume: 36, Issue:11

    Topics: Acetylcysteine; Clinical Trials as Topic; Drug Therapy, Combination; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Prognosis; Pyridones

2013
Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.
    The Annals of pharmacotherapy, 2014, Volume: 48, Issue:12

    Topics: Acetylcysteine; Anti-Inflammatory Agents; Azathioprine; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Prednisone; Pyridones; Randomized Controlled Trials as Topic

2014
Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment.
    Respiratory investigation, 2015, Volume: 53, Issue:1

    Topics: Acetylcysteine; Empirical Research; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Japan; Oximetry; Patient Selection; Pyridones; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Vital Capacity

2015
Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
    BMC pulmonary medicine, 2015, Apr-18, Volume: 15

    Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Treatment Outcome

2015
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
    Chest, 2016, Volume: 149, Issue:3

    Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin

2016
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
    BMC medicine, 2016, Feb-03, Volume: 14

    Topics: Acetylcysteine; Adult; Anticoagulants; Bayes Theorem; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Indoles; Male; Middle Aged; Pyridones; Quality of Life; Treatment Outcome; Young Adult

2016
Efficacy of N-Acetylcysteine in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Medicine, 2016, Volume: 95, Issue:19

    Topics: Acetylcysteine; Expectorants; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Diffusing Capacity; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity

2016
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Pulmonary pharmacology & therapeutics, 2016, Volume: 40

    Topics: Acetylcysteine; Anti-Inflammatory Agents; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Practice Guidelines as Topic; Pyridones; Randomized Controlled Trials as Topic; Treatment Outcome

2016
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    PharmacoEconomics, 2017, Volume: 35, Issue:4

    Topics: Acetylcysteine; Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Markov Chains; Models, Economic; Pyridones; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom

2017
[Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:12

    Topics: Acetylcysteine; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antioxidants; Biopsy; Expectorants; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Pyridones; Tomography, X-Ray Computed

2012
Current and novel drug therapies for idiopathic pulmonary fibrosis.
    Drug design, development and therapy, 2012, Volume: 6

    Topics: Acetylcysteine; Amino Acid Oxidoreductases; Animals; Antiviral Agents; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-13; Lung Transplantation; MicroRNAs; Protein Kinase Inhibitors; Pyridones; Transforming Growth Factor beta

2012

Trials

9 trial(s) available for acetylcysteine and Cryptogenic Fibrosing Alveolitis

ArticleYear
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    BMC pulmonary medicine, 2022, Dec-13, Volume: 22, Issue:1

    Topics: Acetylcysteine; Clinical Trials, Phase III as Topic; Double-Blind Method; Genotype; Humans; Idiopathic Pulmonary Fibrosis; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity

2022
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
    The European respiratory journal, 2021, Volume: 57, Issue:1

    Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Humans; Idiopathic Pulmonary Fibrosis; Japan; Pyridones; Treatment Outcome; Vital Capacity

2021
Treatment switching in idiopathic pulmonary fibrosis: from triple therapy to enrollment into a clinical investigational drug trial.
    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2013, Sep-01, Volume: 30 Suppl 1

    Topics: Acetylcysteine; Azathioprine; Double-Blind Method; Drugs, Investigational; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Treatment Outcome

2013
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
    The New England journal of medicine, 2014, May-29, Volume: 370, Issue:22

    Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Treatment Failure; Vital Capacity

2014
Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: A prospective, single-arm study.
    Respiratory investigation, 2016, Volume: 54, Issue:3

    Topics: Acetylcysteine; Administration, Inhalation; Aged; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Respiratory Function Tests; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity

2016
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:6

    Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Therapy, Combination; Europe; Expectorants; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Treatment Outcome

2016
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
    Respiratory research, 2009, Oct-27, Volume: 10

    Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Exercise Test; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Patient Dropouts; Prednisone; Pulmonary Diffusing Capacity; Respiratory System Agents; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity

2009
[Comments of the DGP on the press release dated 21.10. 2011 of the National Heart, Lung and Blood Institute about the PANTHER Study on IPF patients].
    Pneumologie (Stuttgart, Germany), 2011, Volume: 65, Issue:12

    Topics: Acetylcysteine; Aged; Aged, 80 and over; Azathioprine; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Middle Aged; Placebos; Prednisolone; Randomized Controlled Trials as Topic; Respiratory System Agents; Treatment Outcome

2011
Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.
    Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:3

    Topics: Acetylcysteine; Administration, Inhalation; Aged; Asian People; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Severity of Illness Index; Treatment Outcome; Vital Capacity

2012

Other Studies

42 other study(ies) available for acetylcysteine and Cryptogenic Fibrosing Alveolitis

ArticleYear
Long-circulating thiolated chitosan nanoparticles of nintedanib with N-acetyl cysteine for treating idiopathic pulmonary fibrosis: In vitro assessment of cytotoxicity, antioxidant, and antifibrotic potential.
    International journal of pharmaceutics, 2023, Sep-25, Volume: 644

    Topics: Acetylcysteine; Antioxidants; Cell Line; Cell Survival; Chitosan; Humans; Idiopathic Pulmonary Fibrosis; Nanoparticles; Particle Size; Sulfhydryl Compounds

2023
Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with
    The European respiratory journal, 2021, Volume: 57, Issue:1

    Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Vital Capacity

2021
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
    Pneumologie (Stuttgart, Germany), 2018, Volume: 72, Issue:2

    Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides

2018
N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia.
    BMC pulmonary medicine, 2018, Feb-08, Volume: 18, Issue:1

    Topics: Acetylcysteine; Aged; Antibodies, Antinuclear; Cohort Studies; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Kaplan-Meier Estimate; Lung Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Survival Rate

2018
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:12

    Topics: Acetylcysteine; Biomarkers; Cellular Senescence; Cyclic N-Oxides; Down-Regulation; Etoposide; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mitochondria; Myofibroblasts; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rotenone; Sirolimus

2018
Efficacy of TCM therapy of tonifying lung-kidney's Qi-deficiency in a case of idiopathic pulmonary fibrosis: A case report.
    Medicine, 2019, Volume: 98, Issue:18

    Topics: Acetylcysteine; Carbon Monoxide; Disease Progression; Expectorants; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Kidney; Lung; Male; Medicine, Chinese Traditional; Middle Aged; Pulmonary Diffusing Capacity; Respiratory Function Tests; Treatment Outcome; Vital Capacity; Yin Deficiency

2019
Curcumin induced oxidative stress attenuation by N-acetylcysteine co-treatment: a fibroblast and epithelial cell in-vitro study in idiopathic pulmonary fibrosis.
    Molecular medicine (Cambridge, Mass.), 2019, 06-13, Volume: 25, Issue:1

    Topics: Acetylcysteine; Antioxidants; Cell Survival; Cells, Cultured; Curcumin; Epithelial Cells; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Oxidative Stress; Polymerase Chain Reaction; Reactive Oxygen Species

2019
Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.
    Medicine, 2019, Volume: 98, Issue:30

    Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Medicine, Chinese Traditional; Meta-Analysis as Topic; Network Meta-Analysis; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Respiratory Function Tests; Severity of Illness Index; Survival Analysis; Systematic Reviews as Topic

2019
Idiopathic pulmonary fibrosis in a referral center in Iran: are patients developing the disease at a younger age?
    Archives of Iranian medicine, 2013, Volume: 16, Issue:3

    Topics: Acetylcysteine; Adolescent; Adrenal Cortex Hormones; Adult; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Child; Drug Therapy, Combination; Expectorants; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Iran; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Young Adult

2013
Clinical case: Differential diagnosis of idiopathic pulmonary fibrosis.
    BMC research notes, 2013, Volume: 6 Suppl 1

    Topics: Acetylcysteine; Alveolitis, Extrinsic Allergic; Azathioprine; Diagnosis, Differential; Disease Management; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Prednisolone; Pulmonary Emphysema; Radiography; Smoking

2013
Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Research Group on Diffuse Pulmonary Diseases.
    Archivos de bronconeumologia, 2013, Volume: 49, Issue:8

    Topics: Acetylcysteine; Biopsy; Bronchoalveolar Lavage Fluid; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Contraindications; Diagnostic Imaging; Disease Progression; Evidence-Based Medicine; Gastroesophageal Reflux; Genetic Therapy; Glucocorticoids; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Immunologic Factors; Incidence; Indoles; Lung; Lung Transplantation; Oxygen Inhalation Therapy; Palliative Care; Prevalence; Prognosis; Pulmonary Emphysema; Pyridones; Risk Factors; Spain

2013
Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis.
    Respiratory medicine, 2013, Volume: 107, Issue:11

    Topics: Acetylcysteine; Aged; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Oxygen Inhalation Therapy; Pulmonary Diffusing Capacity; Pulmonary Emphysema; Respiratory Function Tests; Retrospective Studies; Syndrome; Tomography, X-Ray Computed; Total Lung Capacity; Vital Capacity

2013
Combination therapies targeting multiple pathways in idiopathic pulmonary fibrosis (IPF).
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:22

    Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Vital Capacity

2013
Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:22

    Topics: Acetylcysteine; Administration, Inhalation; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Progression; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity

2013
[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française].
    Revue des maladies respiratoires, 2013, Volume: 30, Issue:10

    Topics: Acetylcysteine; Adrenal Cortex Hormones; Antibodies; Anticoagulants; Colchicine; Diagnostic Techniques, Respiratory System; France; Genetic Testing; Humans; Idiopathic Pulmonary Fibrosis; Interdisciplinary Communication; Patient Care Team; Vaccination

2013
Hot off the breath: A big step forward for idiopathic pulmonary fibrosis.
    Thorax, 2014, Volume: 69, Issue:9

    Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Enzyme Inhibitors; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic

2014
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
    Respiration; international review of thoracic diseases, 2014, Volume: 88, Issue:3

    Topics: Acetylcysteine; Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Expectorants; Fatigue; Female; Gastrointestinal Diseases; Germany; Humans; Idiopathic Pulmonary Fibrosis; Male; Medication Adherence; Middle Aged; Pyridones; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; Vital Capacity; Weight Loss

2014
2014 American Thoracic Society International Conference.
    The Lancet. Respiratory medicine, 2014, Volume: 2, Issue:7

    Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Asthma; Congresses as Topic; Eosinophilia; Expectorants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idiopathic Pulmonary Fibrosis; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyridones; Respiratory Distress Syndrome

2014
[Idiopathic pulmonary fibrosis: A new era, new challenges].
    Revue des maladies respiratoires, 2014, Volume: 31, Issue:7

    Topics: Acetylcysteine; Clinical Trials as Topic; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones

2014
Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Respirology (Carlton, Vic.), 2015, Volume: 20, Issue:3

    Topics: Acetylcysteine; Administration, Inhalation; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity

2015
Combination pirfenidone and inhaled N-acetylcysteine therapy for IPF: does it take these two to tango?
    Respirology (Carlton, Vic.), 2015, Volume: 20, Issue:3

    Topics: Acetylcysteine; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones

2015
[Two drugs inhibit disease progression. Idiopathic lung fibrosis treatable for the first time].
    MMW Fortschritte der Medizin, 2015, Feb-05, Volume: 157, Issue:2

    Topics: Acetylcysteine; Disease Progression; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Vital Capacity

2015
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.
    The European respiratory journal, 2015, Volume: 46, Issue:1

    Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Exercise Test; Female; Germany; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyridones; Registries; Steroids; Tomography, X-Ray Computed; Vital Capacity

2015
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.
    American journal of respiratory and critical care medicine, 2015, Dec-15, Volume: 192, Issue:12

    Topics: Acetylcysteine; Aged; Cohort Studies; Female; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Intracellular Signaling Peptides and Proteins; Male; Mucin-5B; Polymorphism, Single Nucleotide; Risk

2015
Genetics affect IPF treatment response to N-acetylcysteine.
    The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:10

    Topics: Acetylcysteine; Drug Therapy, Combination; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis

2015
Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?
    American journal of respiratory and critical care medicine, 2015, Dec-15, Volume: 192, Issue:12

    Topics: Acetylcysteine; Female; Humans; Idiopathic Pulmonary Fibrosis; Intracellular Signaling Peptides and Proteins; Male; Mucin-5B

2015
Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis.
    Respiratory investigation, 2016, Volume: 54, Issue:3

    Topics: Acetylcysteine; Administration, Inhalation; Aged; Disease Progression; Female; Glutathione; Glutathione Disulfide; Humans; Idiopathic Pulmonary Fibrosis; Male; Retrospective Studies; ROC Curve; Vital Capacity

2016
Acetylcysteine in IPF: the knockout blow?
    The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:6

    Topics: Acetylcysteine; Humans; Idiopathic Pulmonary Fibrosis; Pyridones

2016
Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
    The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:5

    Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Proton Pump Inhibitors; Pyridones; Treatment Outcome

2016
Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis.
    BMC pulmonary medicine, 2016, 11-03, Volume: 16, Issue:1

    Topics: Acetylcysteine; Aged; Anti-Bacterial Agents; China; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Oxygen Inhalation Therapy; Prognosis; Pulmonary Emphysema; Retrospective Studies; Severity of Illness Index; Survival Analysis; Tomography, X-Ray Computed; Vital Capacity

2016
Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
    Pharmaceutical biology, 2017, Volume: 55, Issue:1

    Topics: Acetylcysteine; Animals; Bleomycin; Blotting, Western; Caveolin 1; Cytoprotection; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Idiopathic Pulmonary Fibrosis; Lung; Male; Platelet-Derived Growth Factor; Prednisone; Protective Agents; Pyridones; Rats, Wistar; Real-Time Polymerase Chain Reaction; Signal Transduction; Time Factors; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha

2017
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open.
    The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:1

    Topics: Acetylcysteine; Administration, Inhalation; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Vital Capacity

2017
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply.
    The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:1

    Topics: Acetylcysteine; Administration, Inhalation; Humans; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Vital Capacity

2017
Could N-acetylcysteine slow progression of idiopathic pulmonary fibrosis by inhibiting EMT?
    American journal of physiology. Lung cellular and molecular physiology, 2009, Volume: 297, Issue:5

    Topics: Acetylcysteine; Animals; Disease Progression; Drug Therapy, Combination; Epithelium; Humans; Idiopathic Pulmonary Fibrosis; Mesoderm; Pulmonary Alveoli; Rats

2009
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis.
    Lung, 2010, Volume: 188, Issue:2

    Topics: Acetylcysteine; Azathioprine; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; Gene Frequency; Genetic Testing; Genotype; Humans; Idiopathic Pulmonary Fibrosis; Leukopenia; Methyltransferases; Models, Economic; Patient Selection; Pharmacogenetics; Phenotype; Quality-Adjusted Life Years; Respiratory System Agents; Steroids; Treatment Outcome

2010
N-acetylcysteine inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro.
    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2009, Volume: 26, Issue:2

    Topics: Acetylcysteine; Aged; Bronchoalveolar Lavage Fluid; Cells, Cultured; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Macrophages, Alveolar; Male; Receptors, Tumor Necrosis Factor; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha

2009
Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis.
    Internal medicine (Tokyo, Japan), 2010, Volume: 49, Issue:21

    Topics: Acetylcysteine; Administration, Inhalation; Aged; Case-Control Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Respiratory Function Tests; Retrospective Studies; Time Factors; Treatment Outcome

2010
Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis.
    PloS one, 2010, Nov-16, Volume: 5, Issue:11

    Topics: Acetylcysteine; Actins; Blotting, Western; Cell Differentiation; Cell Survival; Cells, Cultured; Collagen Type I; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Free Radical Scavengers; Humans; Hydrogen Peroxide; Idiopathic Pulmonary Fibrosis; Middle Aged; Muscle, Smooth; Oxidants; Phosphorylation; Protein-Tyrosine Kinases; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1

2010
Hot off the breath: triple therapy for idiopathic pulmonary fibrosis--hear the PANTHER roar.
    Thorax, 2012, Volume: 67, Issue:2

    Topics: Acetylcysteine; Aged; Aged, 80 and over; Azathioprine; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Middle Aged; Placebos; Prednisolone; Randomized Controlled Trials as Topic; Respiratory System Agents

2012
Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: comparison between classical thiol-protectant, N-acetyl-L-cysteine, and novel thiol antioxidant, N,N'-bis-2-mercap
    Toxicology mechanisms and methods, 2012, Volume: 22, Issue:5

    Topics: Acetylcysteine; Actin Cytoskeleton; Animals; Antioxidants; Bleomycin; Cattle; Cell Culture Techniques; Cell Survival; Cells, Cultured; Cysteamine; Endothelial Cells; Endothelium, Vascular; Glutathione; Idiopathic Pulmonary Fibrosis; Lung; Microscopy, Fluorescence; Molecular Structure; Oxidation-Reduction; Phthalic Acids; Reactive Oxygen Species; Structure-Activity Relationship; Sulfhydryl Compounds

2012
Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.
    The European respiratory journal, 2012, Volume: 39, Issue:4

    Topics: Acetylcysteine; Azathioprine; Drug Therapy, Combination; Expectorants; Glucocorticoids; Humans; Idiopathic Pulmonary Fibrosis; Immunosuppressive Agents; Prednisolone

2012
N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats.
    Respiration; international review of thoracic diseases, 2012, Volume: 84, Issue:6

    Topics: Acetylcysteine; Actins; Animals; Antibiotics, Antineoplastic; Bleomycin; Collagen; Disease Models, Animal; Down-Regulation; Free Radical Scavengers; Glutathione; Idiopathic Pulmonary Fibrosis; Lung; Male; Protein-Lysine 6-Oxidase; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1

2012